ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
$102.2M
Market Cap • 9/12/2025
2025
IPO
NASDAQ
Listing Exchange
United States
Country
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!